Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
Acurx Pharmaceuticals Analyst Ratings
Acurx Pharmaceuticals Shares Are Trading Higher After the Company Announced Its Preparing to Advance to Phase 3 Clinical Trials to Treat Patients With C. Difficile Infection.
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile Infection Based on Recent FDA and EMA Communications
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 -- Barrons.com
Bitcoin Hits New All-Time High Above $98,000 As Spot ETFs Crack $100 Billion Net Asset Value Milestone
Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment
Acurx Pharmaceuticals(ACXP.US)擬斥最多100萬美元購買比特幣
Acurx Pharmaceuticals Shares Are Trading Lower. The Company Announced Its Board of Directors Approved the Purchase of up to $1 Million in Bitcoin to Hold as a Treasury Reserve Asset.
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Q3 2024 Acurx Pharmaceuticals Inc Earnings Call
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript Summary
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Acurx Pharmaceuticals Q3 2024 GAAP EPS $(0.17) Beats $(0.18) Estimate
Acurx Pharmaceuticals 3Q Loss/Shr 17c >ACXP
Earnings Scheduled For November 13, 2024
データなし